サマリー

ELISpotおよびFluoroSpotアッセイの世界市場規模は、2022年の274百万米ドルから2027年には390百万米ドルに達し、予測期間中に7.3%のCAGRで推移すると予測されます。市場を牽引する要因としては、腫瘍学におけるELISpotおよびFluoroSpotアッセイの使用増加、バイオテクノロジーおよびバイオ医薬品産業の成長などが挙げられます。一方、代替検出技術の利用が可能であることから、今後数年間は市場の成長がある程度制限されると予想されます。

"ELISpotおよびFluoroSpot Assays製品の市場において、予測期間中、Assay kitsが最大の市場シェアを占めた"
ELISpotおよびFluoroSpotアッセイ製品市場は、アッセイキット、アナライザー、および補助製品に区分されます。2021年には、キットは、ELISAなどの他のアッセイと比較して、高い特異性と感度、検出限界の良さなどの利点があることに加え、研究・診断分野での応用範囲が広いことから、大きな市場シェアを占めたという。

"診断用途セグメントが最大の市場シェアを占める"
ELISpotおよびFluoroSpotアッセイ市場は、アプリケーションの種類に基づき、診断アプリケーションと研究アプリケーションに区分されます。2021年には診断用途セグメントが最大の市場シェアを占めたが、ワクチン開発、臨床試験、癌研究など、いくつかの研究用途での実践を考慮すると、2022年から2027年にかけて研究用途が最も速い速度で成長すると予想される。

"APAC地域が最も高いCAGRを占めた"
ELISpotとFluoroSpotアッセイの世界市場は、4つの地域に分けられます。北米、アジア太平洋、欧州、その他の地域です。地域別分析によると、アジア太平洋地域は2021年および将来にわたって大きな市場シェアを維持する可能性が高いとされています。アジア太平洋地域は、非感染性（NCD）の増加、ワクチンに関する研究資金、疾患プロファイルの変化などにより、市場が活性化しています。一方、北米は、主要プレイヤーの存在、技術的に高度なELISpotおよびFluoroSpotアッセイキットとアナライザーの入手が可能なことから、今後数年間で大きな成長を遂げるでしょう。

本レポートのために実施した主なインタビューは以下のように分類されます。

- 企業タイプ別ティア1：32％、ティア2：44％、ティア3：24
- 役職別Cレベル：30％、Dレベル：34％、その他：36
- 地域別地域別：北米40％、欧州28％、アジア太平洋20％、その他の地域12％。
報告書に掲載されている企業名
- オックスフォード・イミュノテック社（英国）
- セルラーテクノロジー社（米国）
- マブテック（スウェーデン）
- ベクトン・ディッキンソン アンド カンパニー（米国）
- アブカム・ピーエルシー(イギリス)
- バイオテクネ(米)
- マイクロジェン・ダイアグノスティーク（ドイツ）
- オートイムン・ダイアグノスティカ社（ドイツ）
- U-CyTech（オランダ）
- メディックスバイオケミカ（フィンランド）
- メルクKGaA（ドイツ）
- バイオシスGmbH（ドイツ）
- Anogen-Yes Biotech Laboratories Ltd（カナダ）
- アブノバ・コーポレーション(台湾)
- Biorbyt Ltd（英国）

リサーチカバレッジ

本レポートでは、ELISpotおよびFluoroSpotアッセイの市場を製品、アプリケーション、エンドユーザー、地域に基づいて調査しています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供します。また、ELISpotおよびFluoroSpot Assaysの市場全体に対する成長動向、展望、貢献度に関して、マイクロマーケットを調査しています。本レポートでは、4つの主要地域に関して、市場セグメントの収益を予測しています。


レポート購入の理由
本レポートは、以下のポイントに関する洞察を提供しています。

市場の浸透。市場の上位25社が提供するELISpotおよびFluoroSpotアッセイ製品に関する包括的な情報。ELISpotおよびFluoroSpotアッセイ市場を製品、アプリケーション、エンドユーザー、地域別に分析しています。
市場開拓。有利な新興市場に関する包括的な情報です。このレポートでは、主要な地域ごとの各種固定装置市場を分析しています。
市場の多様化。ELISpotおよびFluoroSpot Assays市場における未開拓の地域、最近の開発、投資に関する徹底的な情報。
競争力の評価。ELISpotおよびFluoroSpot Assays市場における主要企業の市場占有率および戦略に関する詳細な評価
市場の位置づけ。競合状況をより良く理解し、より良いビジネスの位置付けと適切な市場参入戦略を立てるためのより多くの洞察を得ることができます。

ページTOPに戻る

目次

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS AND EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 GEOGRAPHIC SCOPE 28
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY 29
1.5 LIMITATIONS 29
1.6 MARKET STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Secondary sources 32
2.1.2 PRIMARY DATA 33
FIGURE 2 PRIMARY SOURCES 33
2.1.2.1 Key data from primary sources 34
2.1.2.2 Key industry insights 35
2.1.2.3 Breakdown of primary interviews 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 35
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 36
2.2 MARKET SIZE ESTIMATION 36
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: OXFORD IMMUNOTEC (US) 37
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 37
2.2.1 GROWTH FORECAST 38
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38
FIGURE 8 TOP-DOWN APPROACH 39
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 40
FIGURE 9 DATA TRIANGULATION METHODOLOGY 40
2.4 MARKET SHARE ANALYSIS 41
2.5 STUDY ASSUMPTIONS 41
2.6 RISK ASSESSMENT 41
TABLE 1 RISK ASSESSMENT 41
 
3 EXECUTIVE SUMMARY 42
FIGURE 10 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 42
FIGURE 11 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 43
FIGURE 12 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 43
FIGURE 13 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION) 44
4 PREMIUM INSIGHTS 45
4.1 ELISPOT AND FLUOROSPOT ASSAYS MARKET OVERVIEW 45
FIGURE 14 RISING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 45
4.2 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2022–2027 45
FIGURE 15 ELISPOT ASSAY KITS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 45
4.3 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT AND COUNTRY (2022) 46
FIGURE 16 ASSAYS KITS SEGMENT TO DOMINATE NORTH AMERICAN ELISPOT AND FLUOROSPOT ASSAYS MARKET IN 2022 46
4.4 ELISPOT AND FLUOROSPOT ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
FIGURE 17 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH FROM 2022 TO 2027 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 18 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
5.2.1 DRIVERS 49
5.2.1.1 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis 49
FIGURE 19 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION) 49
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 50
5.2.1.2 Increasing vaccine development to address challenges of antimicrobial resistance 50
5.2.1.3 Increasing use of ELISpot and FluoroSpot assays in oncology 51
TABLE 3 INCIDENCE OF CANCER IN MEN, 2020 52
TABLE 4 INCIDENCE OF CANCER IN WOMEN, 2020 52
5.2.1.4 ELISpot assays as diagnostic tool in drug hypersensitivity reaction 53
TABLE 5 EXAMPLES OF ELISPOT ASSAYS IN DRUG HYPERSENSITIVITY REACTIONS 53
5.2.1.5 Growth in biotechnology and biopharmaceutical industries 54
5.2.2 OPPORTUNITIES 54
5.2.2.1 Use of FluoroSpot assays for multiple-analyte detection in single well 54
5.2.2.2 Growth opportunities in emerging economies 55
FIGURE 20 HEALTHCARE EXPENDITURE PER CAPITA IN BRIC COUNTRIES, 2012–2019 56
5.2.3 CHALLENGES 56
5.2.3.1 Availability of alternative detection technologies 56
5.2.3.2 Dearth of skilled professionals 56
5.2.4 RESTRAINTS 57
5.2.4.1 Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables 57
5.3 RANGES/SCENARIOS 58
FIGURE 21 PESSIMISTIC SCENARIO 58
FIGURE 22 OPTIMISTIC SCENARIO 58
FIGURE 23 REALISTIC SCENARIO 59
5.4 VALUE CHAIN ANALYSIS 59
FIGURE 24 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 59
5.5 SUPPLY CHAIN ANALYSIS 60
FIGURE 25 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 61
5.6 TECHNOLOGY ANALYSIS 61
5.7 PORTER’S FIVE FORCES ANALYSIS 62
5.7.1 THREAT OF NEW ENTRANTS 62
5.7.2 INTENSITY OF COMPETITIVE RIVALRY 62
5.7.3 BARGAINING POWER OF BUYERS 62
5.7.4 BARGAINING POWER OF SUPPLIERS 62
5.7.5 THREAT OF SUBSTITUTES 62
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 63
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 63
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 63
TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%) 63
5.8.2 BUYING CRITERIA 63
FIGURE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS 63
TABLE 7 KEY BUYING CRITERIA FOR TOP THREE END USERS 64
5.9 REGULATORY LANDSCAPE 64
TABLE 8 REGULATORY AUTHORITIES GOVERNING ELISPOT AND FLUOROSPOT ASSAYS MARKET 64
5.9.1 US 65
TABLE 9 US: CLASSIFICATION OF ELISPOT AND FLUOROSPOT ASSAY PRODUCTS 65
FIGURE 28 US: REGULATORY PROCESS FOR IVD DEVICES 66
5.9.2 CANADA 67
FIGURE 29 CANADA: REGULATORY PROCESS FOR IVD DEVICES 67
5.9.3 EUROPE 67
TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES 68
5.9.4 JAPAN 69
FIGURE 30 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 69
TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 69
5.9.5 CHINA 70
TABLE 12 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 70
5.9.6 INDIA 71
FIGURE 31 INDIA: REGULATORY PROCESS FOR IVD DEVICES 71
5.9.7 RUSSIA 71
TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES 71
5.9.8 SAUDI ARABIA 72
TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 72
5.9.9 MEXICO 72
FIGURE 32 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 72
TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 73
5.9.10 BRAZIL 74
FIGURE 33 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 74
5.9.11 SOUTH KOREA 74
TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 74
5.9.12 MIDDLE EAST 75
5.9.13 AFRICA 75
5.10 KEY CONFERENCES AND EVENTS IN 2022 AND 2023 75
TABLE 17 LIST OF CONFERENCES AND EVENTS 75
5.11 PATENT ANALYSIS 76
5.12 PRICING ANALYSIS 77
TABLE 18 ELISPOT AND FLUOROSPOT ASSAYS MARKET: PRICE RANGE FOR ELISPOT AND FLUOROSPOT ASSAY PRODUCTS 77
5.13 TRADE ANALYSIS 77
5.13.1 TRADE ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS 77
TABLE 19 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017–2021 (USD MILLION) 78
TABLE 20 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017–2021 (USD MILLION) 78
5.14 ECOSYSTEM ANALYSIS 78
5.14.1 ROLE IN ECOSYSTEM 79
FIGURE 34 KEY PLAYERS OPERATING IN ELISPOT AND FLUOROSPOT ASSAYS MARKET 79
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80
6 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT 81
6.1 INTRODUCTION 82
TABLE 21 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 82
6.2 ASSAY KITS 82
TABLE 22 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 83
6.2.1 ASSAY KITS MARKET, BY TECHNIQUE 83
TABLE 23 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 83
6.2.1.1 ELISpot assay kits 83
6.2.1.1.1 Need for highly sensitive immune monitoring requirements in clinical trials to drive market 83
TABLE 24 ELISPOT ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 84
6.2.1.2 FluoroSpot assay kits 84
6.2.1.2.1 Increasing demand for multiple analyte detection and technological advancements to support market growth 84
TABLE 25 FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 84
6.2.2 ASSAY KITS MARKET, BY UTILITY 85
TABLE 26 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY UTILITY, 2020–2027 (USD MILLION) 85
6.2.2.1 Diagnostic kits 85
6.2.2.1.1 Used for detection of infectious and autoimmune diseases 85
TABLE 27 DIAGNOSTIC KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 85
6.2.2.2 Research kits 86
6.2.2.2.1 Continued investment in vaccine research, clinical trials, and cancer research to drive market 86
TABLE 28 RESEARCH KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 86
6.2.3 ASSAY KITS MARKET, BY ANALYTE 86
TABLE 29 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY ANALYTE, 2020–2027 (USD MILLION) 86
6.2.3.1 T-cell-based kits 87
6.2.3.1.1 Low concentrations of infection-released analytes necessitate use of T-cell-based kits 87
TABLE 30 T-CELL-BASED KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 87
6.2.3.2 B-cell-based kits 87
6.2.3.2.1 Detection of B-cell-based antibodies useful to study cell response post-infection/vaccination 87
TABLE 31 B-CELL-BASED KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 87
6.2.3.3 Other analyte kits 88
TABLE 32 OTHER ANALYTE KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 88
6.3 ANALYZERS 88
6.3.1 ADOPTION OF ASSAY KITS TO DRIVE USE OF ANALYZERS 88
TABLE 33 ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 88
6.4 ANCILLARY PRODUCTS 89
6.4.1 MARKET PLAYERS SUCH AS THERMO FISHER SCIENTIFIC PROVIDE ANCILLARY PRODUCTS 89
TABLE 34 ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION) 89
 
7 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION 90
7.1 INTRODUCTION 91
TABLE 35 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91
7.2 DIAGNOSTIC APPLICATIONS 91
TABLE 36 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 37 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 92
7.2.1 INFECTIOUS DISEASES 92
7.2.1.1 Infectious diseases segment dominates diagnostic applications market 92
FIGURE 35 US: TOTAL CASES OF TICKBORNE DISEASES, 2004–2019 92
TABLE 38 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 93
7.2.2 TRANSPLANTS 93
7.2.2.1 Growing incidence of infections caused during transplant procedures to drive demand for ELISpot and FluoroSpot assays 93
TABLE 39 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY REGION, 2020–2027 (USD MILLION) 93
7.3 RESEARCH APPLICATIONS 94
TABLE 40 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 41 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 94
7.3.1 VACCINE DEVELOPMENT 94
7.3.1.1 Largest and fastest-growing segment of market 94
TABLE 42 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 95
7.3.2 CLINICAL TRIALS 95
7.3.2.1 Growing number of clinical trials to drive demand for ELISpot and FluoroSpot assays 95
FIGURE 36 NUMBER OF CLINICAL TRIALS, BY REGION, 2010–2021 95
TABLE 43 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY REGION, 2020–2027 (USD MILLION) 96
7.3.3 CANCER RESEARCH 96
7.3.3.1 Rising prevalence of cancer to support market growth 96
TABLE 44 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY REGION, 2020–2027 (USD MILLION) 97
8 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER 98
8.1 INTRODUCTION 99
TABLE 45 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 99
8.2 HOSPITAL AND CLINICAL LABORATORIES 99
8.2.1 LARGEST END USERS OF ELISPOT AND FLUOROSPOT ASSAYS 99
TABLE 46 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 100
8.3 RESEARCH INSTITUTES 100
8.3.1 FASTEST-GROWING END USERS OF ELISPOT AND FLUOROSPOT ASSAYS 100
TABLE 47 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 100
8.4 BIOPHARMACEUTICAL COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 101
8.4.1 BIOPHARMACEUTICAL COMPANIES AND CROS USE ELISPOT AND FLUOROSPOT ASSAYS FOR VACCINE DEVELOPMENT, CLINICAL TRIALS, AND CANCER RESEARCH 101
TABLE 48 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2020–2027 (USD MILLION) 102
9 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION 103
9.1 INTRODUCTION 104
TABLE 49 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 104
9.2 NORTH AMERICA 104
FIGURE 37 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT 105
TABLE 50 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 51 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 106
TABLE 52 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 106
TABLE 53 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 106
9.2.1 US 107
9.2.1.1 US dominates North American ELISpot and FluoroSpot assays market 107
TABLE 54 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 107
TABLE 55 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 108
TABLE 56 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 108
9.2.2 CANADA 108
9.2.2.1 High burden of chronic diseases and rising healthcare expenditure to drive adoption of ELISpot and FluoroSpot assays 108
TABLE 57 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 109
TABLE 58 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
TABLE 59 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 110
 
9.3 EUROPE 110
FIGURE 38 GLOBAL VACCINE PRODUCTION 111
TABLE 60 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 61 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 112
TABLE 62 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112
TABLE 63 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 112
9.3.1 GERMANY 113
9.3.1.1 Fastest-growing country in European ELISpot and FluoroSpot assays market 113
TABLE 64 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 113
TABLE 65 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
TABLE 66 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 114
9.3.2 UK 114
9.3.2.1 Rising prevalence of NCDs to drive market 114
TABLE 67 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 115
TABLE 68 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 115
TABLE 69 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 115
9.3.3 FRANCE 116
9.3.3.1 Need for early disease diagnosis to support market growth 116
TABLE 70 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 116
TABLE 71 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116
TABLE 72 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 117
9.3.4 ITALY 117
9.3.4.1 Growing geriatric population and increasing support for research to support market 117
TABLE 73 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 118
TABLE 74 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 118
TABLE 75 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 118
9.3.5 SPAIN 119
9.3.5.1 High incidence of chronic diseases to drive market 119
TABLE 76 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 119
TABLE 77 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 120
TABLE 78 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 120
9.3.6 REST OF EUROPE 120
TABLE 79 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 121
TABLE 80 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 81 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 121
9.4 ASIA PACIFIC 122
FIGURE 39 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT 122
TABLE 82 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 83 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 123
TABLE 84 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
TABLE 85 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 124
9.4.1 CHINA 124
9.4.1.1 Rising focus on vaccine development and cancer research to drive market 124
TABLE 86 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 125
TABLE 87 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 125
TABLE 88 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 125
9.4.2 JAPAN 126
9.4.2.1 Increased focus on vaccine research and rising prevalence of chronic diseases to drive market 126
TABLE 89 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 126
TABLE 90 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 127
TABLE 91 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 127
9.4.3 INDIA 127
9.4.3.1 High incidence of chronic diseases and growing vaccine R&D activity to drive market 127
TABLE 92 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 128
TABLE 93 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 94 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
9.4.4 REST OF ASIA PACIFIC 129
TABLE 95 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 130
TABLE 96 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 130
TABLE 97 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 130
9.5 REST OF THE WORLD 131
TABLE 98 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 131
TABLE 99 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 100 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 131
10 COMPETITIVE LANDSCAPE 132
10.1 OVERVIEW 132
10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 132
TABLE 101 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET 132
10.3 REVENUE SHARE ANALYSIS 133
FIGURE 40 REVENUE ANALYSIS OF KEY PUBLIC PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET 133
10.4 MARKET SHARE ANALYSIS 133
TABLE 102 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DEGREE OF COMPETITION 133
10.5 COMPANY EVALUATION QUADRANT 134
10.5.1 STARS 135
10.5.2 EMERGING LEADERS 135
10.5.3 PERVASIVE PLAYERS 135
10.5.4 PARTICIPANTS 135
FIGURE 41 COMPANY EVALUATION QUADRANT: ELISPOT AND FLUOROSPOT ASSAYS MARKET, 2021 136
10.6 COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS 137
10.6.1 PROGRESSIVE COMPANIES 137
10.6.2 STARTING BLOCKS 137
10.6.3 RESPONSIVE COMPANIES 137
10.6.4 DYNAMIC COMPANIES 137
FIGURE 42 COMPANY EVALUATION MATRIX FOR SMES/STARTUPS: ELISPOT AND FLUOROSPOT ASSAYS MARKET, 2021 138
10.7 FOOTPRINT ANALYSIS OF COMPANIES 139
TABLE 103 FOOTPRINT ANALYSIS OF COMPANIES 139
TABLE 104 PRODUCT FOOTPRINT OF COMPANIES 140
TABLE 105 REGIONAL FOOTPRINT OF COMPANIES 141
 
10.8 COMPETITIVE BENCHMARKING 142
TABLE 106 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 142
10.9 COMPETITIVE SCENARIO 142
10.9.1 PRODUCT LAUNCHES 142
TABLE 107 KEY PRODUCT LAUNCHES 142
10.9.2 DEALS 143
TABLE 108 KEY DEALS 143
10.9.3 OTHER DEVELOPMENTS 143
TABLE 109 OTHER KEY DEVELOPMENTS 143
11 COMPANY PROFILES 144
11.1 KEY PLAYERS 144
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1.1 OXFORD IMMUNOTEC LTD. (SUBSIDIARY OF PERKINELMER, INC.) 144
TABLE 110 OXFORD IMMUNOTEC LTD.: BUSINESS OVERVIEW 144
FIGURE 43 OXFORD IMMUNOTEC LTD. (SUBSIDIARY OF PERKINELMER, INC.): COMPANY SNAPSHOT (2022) 145
11.1.2 BECTON, DICKINSON AND COMPANY 147
TABLE 111 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 147
FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 148
11.1.3 CELLULAR TECHNOLOGY LIMITED 151
TABLE 112 CELLULAR TECHNOLOGY LIMITED: BUSINESS OVERVIEW 151
11.1.4 MABTECH 153
TABLE 113 MABTECH: BUSINESS OVERVIEW 153
11.1.5 ABCAM PLC 155
TABLE 114 ABCAM PLC: BUSINESS OVERVIEW 155
FIGURE 45 ABCAM PLC: COMPANY SNAPSHOT (2021) 156
11.1.6 BIO-TECHNE 157
TABLE 115 BIO-TECHNE: BUSINESS OVERVIEW 157
FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022) 158
11.1.7 MERCK KGAA 160
TABLE 116 MERCK KGAA: BUSINESS OVERVIEW 160
FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2021) 161
11.1.8 AUTOIMMUN DIAGNOSTIKA GMBH 163
TABLE 117 AUTOIMMUN DIAGNOSTIKA GMBH: BUSINESS OVERVIEW 163
11.1.9 U-CYTECH 164
TABLE 118 U-CYTECH: BUSINESS OVERVIEW 164
11.1.10 MIKROGEN DIAGNOSTIK 166
TABLE 119 MIKROGEN DIAGNOSTIK: BUSINESS OVERVIEW 166
11.1.11 MEDIX BIOCHEMICA 167
TABLE 120 MEDIX BIOCHEMICA: BUSINESS OVERVIEW 167
11.1.12 ABNOVA CORPORATION 169
TABLE 121 ABNOVA CORPORATION: BUSINESS OVERVIEW 169
11.1.13 ANOGEN-YES BIOTECH LABORATORIES LTD. 170
TABLE 122 ANOGEN-YES BIOTECH LABORATORIES LTD.: BUSINESS OVERVIEW 170
11.1.14 BIORBYT LTD. 171
TABLE 123 BIORBYT LTD.: BUSINESS OVERVIEW 171
11.1.15 BIO-SYS GMBH 173
TABLE 124 BIO-SYS GMBH: BUSINESS OVERVIEW 173
11.2 OTHER PLAYERS 174
11.2.1 JACKSON IMMUNORESEARCH INC. 174
TABLE 125 JACKSON IMMUNORESEARCH INC.: BUSINESS OVERVIEW 174
11.2.2 IST SCIENTIFIC LTD. 175
TABLE 126 IST SCIENTIFIC LTD.: BUSINESS OVERVIEW 175
11.2.3 SERVA ELECTROPHORESIS GMBH 176
TABLE 127 SERVA ELECTROPHORESIS GMBH: BUSINESS OVERVIEW 176
11.2.4 KRISHGEN BIOSYSTEMS 177
TABLE 128 KRISHGEN BIOSYSTEMS: BUSINESS OVERVIEW 177
11.2.5 NATIONAL ANALYTICAL CORPORATION 178
TABLE 129 NATIONAL ANALYTICAL CORPORATION: BUSINESS OVERVIEW 178
11.2.6 STEMCELL TECHNOLOGIES INC. 179
TABLE 130 STEMCELL TECHNOLOGIES INC.: BUSINESS OVERVIEW 179
11.2.7 ZENBIO, INC. 180
TABLE 131 ZENBIO, INC.: BUSINESS OVERVIEW 180
11.2.8 BOC SCIENCES 181
TABLE 132 BOC SCIENCES: BUSINESS OVERVIEW 181
11.2.9 TOKYO CHEMICAL INDUSTRY CO., LTD. 182
TABLE 133 TOKYO CHEMICAL INDUSTRY CO., LTD.: BUSINESS OVERVIEW 182
11.2.10 MP BIOMEDICALS 183
TABLE 134 MP BIOMEDICALS: BUSINESS OVERVIEW 183
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX 184
12.1 INDUSTRY INSIGHTS 184
12.2 DISCUSSION GUIDE 185
12.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 189
12.4 CUSTOMIZATION OPTIONS 191
12.5 RELATED REPORTS 191
12.6 AUTHOR DETAILS 192